{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-280283","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.276888+00:00","generated_at":"2026-06-07T23:26:11.945335+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IN8bio's INB-200 Phase 1 trial: all patients completing doses exceed 7-month PFS; one remains alive at 28.5+ months","bullets":["All ten patients who completed mandated doses exceeded progression-free survival (PFS) of 7 months, exceeding standard-of-care median PFS of 4-7 months.","One patient with IDH-mutant glioma remains alive and progression-free at 28.5+ months (median PFS for IDH-mutant patients in NEJM control arm: 11.1 months).","No treatment-related serious adverse events, dose-limiting toxicities, cytokine release syndrome, infusion reactions, or ICANS reported.","Three dosing cohorts: Cohort 1 (1 dose, 3 pts), Cohort 2 (3 doses, 4 pts), Cohort 3 (6 doses, 3 pts); additional enrollment in Cohort 3 expected to complete in 2023.","Preserved gamma-delta T cells found in relapsed tumor 148 days after initial DRI infusion, indicating durability of cells."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-280283","json":"https://secwatch.observer/filing/0001193125-23-280283.json","markdown":"https://secwatch.observer/filing/0001193125-23-280283.md","text":"https://secwatch.observer/filing/0001193125-23-280283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523280283/0001193125-23-280283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523280283/d900996d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:26:11.945335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}